Aims to reduce chemotherapy-related hospital readmissions by 50% and save over $6 billion annually in healthcare costs.
Founders
Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, Alvaro Sanchez-Ferro
Company Description
Leuko is a startup spun out from MIT and the Madrid M+Vision Consortium, developing a platform technology, PointCheckTM, that combines optics and AI to make noninvasive blood testing easier, faster, and more accessible than state-of-the-art solutions.
Market
Cancer chemotherapy patients
Location
Boston,
MA,
USA
Coinvestors
Good Growth Capital, HTHIAG Capital Partners, Nina Capital